Earnings Feed
Start Free
ADMA BIOLOGICS, INC.·4

Mar 9, 9:14 AM ET

ELMS STEVE 4

Research Summary

AI-generated summary

Updated

ADMA Director Steve Elms Buys 14,000 Shares in Open Market

What Happened Steve Elms, a director of ADMA Biologics, bought a total of 14,000 shares of ADMA common stock in open-market transactions — 7,000 shares on March 5, 2026 at a weighted average price of $15.67 ($109,690) and 7,000 shares on March 6, 2026 at a weighted average price of $15.39 ($107,730). The combined cash outlay for both purchases was approximately $217,420. These were purchases (insider buys), not sales or option exercises.

Key Details

  • Transaction dates and prices:
    • Mar 5, 2026 — 7,000 shares, weighted avg $15.67 (individual trade prices ranged $15.58–$15.74) — $109,690 (Footnote F1).
    • Mar 6, 2026 — 7,000 shares, weighted avg $15.39 (individual trade prices ranged $15.35–$15.42) — $107,730 (Footnote F4).
  • Total shares acquired: 14,000; total value ≈ $217,420.
  • Reported holdings after transaction (per filing footnotes): 2,031,730 shares held by Aisling Capital II LP, 14,000 shares held by Aisling Arcturus Partners (the 14,000 include these purchases), plus 87,330 shares reported as owned by Mr. Elms personally. The filing also notes 10,690 restricted stock units (vest Feb 9, 2027) (Footnotes F3, F5).
  • Disclosure notes: Mr. Elms is a designee of Aisling Capital and may be deemed to beneficially own shares held by Aisling entities but disclaims beneficial ownership except to the extent of any pecuniary interest (Footnote F3).
  • Additional procedural note: The filing includes a commitment to provide a detailed breakdown of trades within the reported price ranges upon request (Footnote F2).
  • Timeliness: Form 4 was filed on Mar 9, 2026 for transactions on Mar 5–6, 2026 — the filing appears timely under the 2-business-day rule.

Context These were straightforward open-market purchases (transaction code P) rather than exercises, awards, or gifts. Purchases by directors can be of interest to investors as one data point about insider buying activity, but they should be considered alongside other information (company fundamentals, institutional holdings, and broader market activity). The filing clarifies the mix of personal and fund-held shares and includes unvested RSUs that vest in 2027.